Literature DB >> 2541050

Mutational analysis of the herpes simplex virus trans-inducing factor Vmw65.

G Werstuck1, J P Capone.   

Abstract

Vmw65 is a structural component of herpes simplex virus which, in conjunction with host factors, trans-activates the expression of the viral immediate-early genes. In order to examine the relationship between the primary structure of Vmw65 and its trans-activating function, we generated in-frame insertion, deletion, and nonsense mutations in a cloned copy of the gene. The ability of the mutant polypeptides to function as transcriptional activators was assessed by transient transfection of Vero cells using, as the reporter gene, the Escherichia coli chloramphenicol acetyltransferase (cat) gene linked to the promoter-regulatory region from the HSV-1 immediate-early gene coding for Vmw175. These studies have demonstrated that a highly acidic region near the C-terminus of Vmw65 as well as the structural integrity of several other regions of the polypeptide are essential for its transactivating properties, whereas a small region near the N-terminus of the polypeptide is dispensible for activity. Finally, in vivo competition studies using inactive deletion mutants suggest that a domain of the polypeptide located between amino acids 141 and 185 may be involved in protein-protein interactions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2541050     DOI: 10.1016/0378-1119(89)90267-9

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  29 in total

1.  A trans-acting peptide activates the yeast a1 repressor by raising its DNA-binding affinity.

Authors:  M R Stark; D Escher; A D Johnson
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

2.  The VP16 paradox: herpes simplex virus VP16 contains a long-range activation domain but within the natural multiprotein complex activates only from promoter-proximal positions.

Authors:  M Hagmann; O Georgiev; W Schaffner
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Differences in determinants required for complex formation and transactivation in related VP16 proteins.

Authors:  M Grapes; P O'Hare
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 4.  Dolichol phosphate mannose synthase: a Glycosyltransferase with Unity in molecular diversities.

Authors:  Dipak K Banerjee; Zhenbo Zhang; Krishna Baksi; Jesús E Serrano-Negrón
Journal:  Glycoconj J       Date:  2017-06-14       Impact factor: 2.916

5.  HCF-dependent nuclear import of VP16.

Authors:  S La Boissière; T Hughes; P O'Hare
Journal:  EMBO J       Date:  1999-01-15       Impact factor: 11.598

6.  Phosphorylation of the VP16 transcriptional activator protein during herpes simplex virus infection and mutational analysis of putative phosphorylation sites.

Authors:  Søren Ottosen; Francisco J Herrera; James R Doroghazi; Angela Hull; Sheenu Mittal; William S Lane; Steven J Triezenberg
Journal:  Virology       Date:  2005-11-17       Impact factor: 3.616

7.  A cellular factor binds to the herpes simplex virus type 1 transactivator Vmw65 and is required for Vmw65-dependent protein-DNA complex assembly with Oct-1.

Authors:  P Xiao; J P Capone
Journal:  Mol Cell Biol       Date:  1990-09       Impact factor: 4.272

8.  Enhanced infectivity of herpes simplex virus type 1 viral DNA in a cell line expressing the trans-inducing factor Vmw65.

Authors:  G Werstuck; P Bilan; J P Capone
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

9.  The extreme carboxyl terminus of the equine herpesvirus 1 homolog of herpes simplex virus VP16 is essential for immediate-early gene activation.

Authors:  G D Elliott
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  Protein and DNA elements involved in transactivation of the promoter of the bovine herpesvirus (BHV) 1 IE-1 transcription unit by the BHV alpha gene trans-inducing factor.

Authors:  V Misra; A C Bratanich; D Carpenter; P O'Hare
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.